CA3231869A1 - Ibudilast in combination therapy for use in the treatment of glioblastoma - Google Patents

Ibudilast in combination therapy for use in the treatment of glioblastoma Download PDF

Info

Publication number
CA3231869A1
CA3231869A1 CA3231869A CA3231869A CA3231869A1 CA 3231869 A1 CA3231869 A1 CA 3231869A1 CA 3231869 A CA3231869 A CA 3231869A CA 3231869 A CA3231869 A CA 3231869A CA 3231869 A1 CA3231869 A1 CA 3231869A1
Authority
CA
Canada
Prior art keywords
day
ibudilast
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231869A
Other languages
English (en)
French (fr)
Inventor
Kazuko Matsuda
Michael VOGELBAUM
Justin Lathia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CA3231869A1 publication Critical patent/CA3231869A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3231869A 2021-09-21 2022-09-19 Ibudilast in combination therapy for use in the treatment of glioblastoma Pending CA3231869A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246755P 2021-09-21 2021-09-21
US63/246,755 2021-09-21
PCT/US2022/044003 WO2023049075A1 (en) 2021-09-21 2022-09-19 Ibudilast in combination therapy for use in the treatment of glioblastoma

Publications (1)

Publication Number Publication Date
CA3231869A1 true CA3231869A1 (en) 2023-03-30

Family

ID=83688651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231869A Pending CA3231869A1 (en) 2021-09-21 2022-09-19 Ibudilast in combination therapy for use in the treatment of glioblastoma

Country Status (6)

Country Link
US (1) US20230090534A1 (https=)
EP (1) EP4404928A1 (https=)
JP (1) JP2024535880A (https=)
CN (1) CN118139619A (https=)
CA (1) CA3231869A1 (https=)
WO (1) WO2023049075A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395747B1 (en) 1998-08-10 2002-05-28 Sauro Sakoda Remedies for multiple sclerosis
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
US8138201B2 (en) 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AU2014319921A1 (en) * 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
WO2018119262A1 (en) * 2016-12-22 2018-06-28 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP2021512921A (ja) * 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
WO2020028134A1 (en) * 2018-07-30 2020-02-06 Fred Hutchinson Cancer Research Center Methods and compositions for treating cancer

Also Published As

Publication number Publication date
CN118139619A (zh) 2024-06-04
JP2024535880A (ja) 2024-10-02
US20230090534A1 (en) 2023-03-23
EP4404928A1 (en) 2024-07-31
WO2023049075A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US20250073213A1 (en) Treatment of progressive neurodegenerative disease with ibudilast
US11446283B2 (en) Methods and dosing regimens using ibudilast and a second agent for cancer therapy
US10391085B2 (en) Methods of treating glioblastoma multiforme using ibudilast
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
US12171752B2 (en) Methods of treating post-COVID condition(s)
US10946071B2 (en) Combination of ibudilast and interferon-beta and methods of using same

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702